Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GenSci143, a bispecific antibody-drug conjugate targeting B7-H3 and PSMA [1] Group 1 - GenSci143 is designed to have dual therapeutic potential through targeted chemotherapy and tumor immunotherapy [1] - The drug works by binding to B7-H3 or PSMA, internalizing into lysosomes, and releasing TOPO-I inhibitor toxins to kill B7-H3 positive, PSMA positive, and double positive tumor cells [1] - GenSci143 utilizes independently developed linker technology, which features strong toxin activity and high plasma stability of the linker, aiming for enhanced tumor-killing effects and improved potential safety [1]